19672-61-8

Basic information

• Product Name: 4-BROMO-4'-CHLOROCHALCONE
• Synonyms: 4-BROMO-4'-CHLOROCHALCONE;3-(4-BROMO-PHENYL)-1-(4-CHLORO-PHENYL)-PROPENONE
• CAS NO: 19672-61-8
• Molecular Formula: C₁₅H₁₀BrClO
• Molecular Weight: 321.6
• Mol File: 19672-61-8.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 436 °C at 760 mmHg
• Flash Point: 217.5 °C
• Appearance: /
• Density: 1.475 g/cm³
• CAS DataBase Reference: 4-BROMO-4'-CHLOROCHALCONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-4'-CHLOROCHALCONE(19672-61-8)
• EPA Substance Registry System: 4-BROMO-4'-CHLOROCHALCONE(19672-61-8)

Safety Data

• Hazardous Substances Data: 19672-61-8(Hazardous Substances Data)

Usage

Description

4-BROMO-4'-CHLOROCHALCONE is a chemical compound belonging to the class of chalcones, characterized as a yellow solid with a molecular formula of C15H9BrClO and a molecular weight of 311.59 g/mol. It is recognized for its potential as an antibacterial, antifungal, anti-inflammatory, and anti-cancer agent, and is utilized as a building block in organic synthesis for creating various biologically active compounds.

Uses

Used in Pharmaceutical Industry:
4-BROMO-4'-CHLOROCHALCONE is used as an antibacterial and antifungal agent for its demonstrated activity against a range of pathogens, making it a promising candidate for the development of new pharmaceuticals.
Used in Anti-inflammatory Applications:
4-BROMO-4'-CHLOROCHALCONE is used as an anti-inflammatory agent, leveraging its potential to reduce inflammation and alleviate related symptoms.
Used in Anti-cancer Applications:
4-BROMO-4'-CHLOROCHALCONE is used as an anti-cancer agent, showing promise in the development of new pharmaceuticals for cancer treatment.
Used in Organic Synthesis:
4-BROMO-4'-CHLOROCHALCONE is used as a building block in organic synthesis for the preparation of various biologically active compounds, contributing to the advancement of medicinal chemistry.

Upstream product

• 99-91-2 para-chloroacetophenone 
• 1122-91-4 4-bromo-benzaldehyde 
• 873-73-4 4-n-chlorophenylacetylene 

Downstream Products

• 1217356-21-2 5-(4-bromophenyl)-7-(4-chlorophenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 1450853-33-4 C₂₄H₁₄BrClO₃ 

Relevant articles and documents

Catalyst- and acid-free Markovnikov hydration of alkynes in a sustainable H2O/ethyl lactate system

An efficient and sustainable protocol for the hydration of alkynes has been developed under metal/acid/catalyst/ligand-free conditions in a water/ethyl lactate mixture. The hydrogen-bond network in the ethyl lactate and water mixture plays a crucial and decisive role in activating the alkynes for hydration to afford the corresponding methyl ketones. This strategy gives the Markovnikov (ketone) addition product selectively over other possible products. The essential role of hydrogen bonding has been confirmed by experimental and theoretical techniques. A probable mechanism has been suggested by various control tests. The efficacy of the method has been further explored for the competent production of value-added α,β-unsaturated carbonyl compounds through the reaction of aldehydes with alkynes as ketonic surrogates. The environmentally benign hydration method takes place under mild conditions, has broad functional-group compatibility, and uses the ethyl lactate/water (1:3) medium as a “green alternative” in the absence of any hazardous, harmful, or expensive substances.

Environment Friendly Synthesis of N′-(1,3-Diphenylallylidene)-1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carbohydrazides: Crystal Structure and Their Anti-oxidant Potential

An environment friendly synthesis of novel hybrid pharmacophores derived from synergism of nalidixic acid and 1,3-diphenylprop-2-en-1-ones is described. Percent yield and reaction times of microwave assisted reactions have been compared with the reactions

Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives

Numerous studies have shown that chalcones are promising scaffolds for the development of new monoamine oxidase-B (MAO-B) inhibitors. As a continuation of our ongoing research into the development of reversible human MAO-B (hMAO-B) inhibitors, two series